Surface marker profiles on lung lymphocytes may predict the mechanism of immune-mediated pneumonitis triggered by tumor-infiltrating lymphocytes in lung cancer patients treated with pembrolizumab

Oda, Kazuhiro; Kato, Kaori; Nakamura, Midori; Jotatsu, Takanobu; Noguchi, Shingo; Kawanami, Toshinori; Kido, Takashi; Yatera, Kazuhiro

doi:10.1016/j.lungcan.2018.02.012

Cited by 15 publications

(11 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two of the three patients had been treated with long-term corticosteroids and immunosuppressants for lung injury. In addition, Sawai et al reported a case [ 20 ] that died 21 days after the onset of lung injury, and Oda et al reported a case [ 21 ] that died 23 days after the onset of lung injury. Therefore, lung injury associated with irAE does not always result in death within a few days after onset.…”

Section: Discussionmentioning

confidence: 99%

Immune-related adverse events caused by treatment with pembrolizumab in a patient with lung cancer who infected influenza virus

Takemura¹,

Motegi²,

Kuroiwa³

et al. 2021

Respiratory Medicine Case Reports

View full text Add to dashboard Cite

A 67-year-old man with stage IV B lung adenocarcinoma was treated with pembrolizumab. The patient was admitted to the hospital because of influenza on the day of the second cycle of pembrolizumab treatment. He was diagnosed with pneumonia and was treated with antiviral drugs and steroids. However, the patient eventually died. In this case, treatment with immune checkpoint inhibitors might have affected the immune response caused by influenza virus infection, that might have caused lung injury, which is an immune-related adverse event (irAE). Hence, it is important that, caution should be taken to prevent transmission of viral infection, and Therefore, it is important to prevent viral infections, but caution should also be paid to the possibility that infections may cause irAEs in patients with lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Immune-related adverse events caused by treatment with pembrolizumab in a patient with lung cancer who infected influenza virus

Takemura¹,

Motegi²,

Kuroiwa³

et al. 2021

Respiratory Medicine Case Reports

View full text Add to dashboard Cite

show abstract

“…Therefore, how to screen for potential patients and how to improve the efficacy of ICIs through combination therapies are 2 promising research directions in the future. The molecular markers reported to be related to the therapeutic effect of ICIs include the expression of programmed death-ligand 1 (PD-L1) on tumor cells, tumor mutation burden, microsatellite instability, tumor infiltrating lymph node cells, and neoplastic antigen, among others (14)(15)(16)(17)(18). In addition, some clinical trials have shown that combining chemotherapy, targeted therapy, and radiotherapy can improve the response rate to ICIs (19)(20)(21)(22).…”

Section: Introductionmentioning

confidence: 99%

Real-world experience with pembrolizumab in patients with advanced soft tissue sarcoma

Liu¹,

Fan²,

Bai³

et al. 2021

Ann Transl Med

View full text Add to dashboard Cite

Background: The goal of this study was to retrospectively analyze the efficacy and safety of pembrolizumab in the real-world treatment of soft tissue sarcoma (STS).Methods: We analyzed 38 patients who suffered from STS and received pembrolizumab treatment from July 2017 to December 2018 in our hospital. We investigated the influence of clinical characteristics, treatment timing, and treatment protocol on objective response rate (ORR). We also investigated the factors affecting overall survival (OS) and progression-free survival (PFS), as well as the occurrence of severe adverse events (SAEs).Results: The overall ORR was 19.4% (7/36). The ORRs of patients who received pembrolizumab treatment as first-line, second-line, and third-line therapy were 42.9% (3/7), 25.0% (4/16), and 0% (0/13), respectively, which showed marginal significance (P=0.052). Four patients (11.1%) maintained a complete response (CR) or partial response (PR) for at least 6 months with pembrolizumab monotherapy, or after withdrawal of chemotherapy or targeted therapy regimens. The median PFS was 2.9 months [95% confidence interval (CI): 2.4-3.4 months] and the median OS was 12.0 months (95% CI: 10.2-13.8 months).Cox regression analysis showed that treatment time was an independent factor affecting PFS (P=0.041), while Eastern Cooperative Oncology Group (ECOG) performance status (PS) score was the only independent factor affecting OS (P=0.028). Conclusions:In the real world, the effectiveness of pembrolizumab in the treatment of STS was low. Some subtypes showed a limited response to pembrolizumab, including alveolar soft part sarcoma (ASPS), undifferentiated pleomorphic sarcoma (UPS), exoskeletal chondrosarcoma (ESCS), and angiosarcoma (AS), while the response in leiomyosarcoma (LMS) was low. Combination therapy may increase the risk of SAEs, especially when combined with pazopanib.

show abstract

“…Another important aspect of this study is that VWCE expression is associated with the immune in ltration levels in breast cancer. Some studies have shown that tumor-in ltrating immune cells are prognostic markers of tumor progression [40][41][42]. Therefore, we hypothesized that VWCE expression is associated with immune in ltration in breast cancer, and is a potential marker of the tumor immune microenvironment.…”

Section: Discussionmentioning

confidence: 95%

VWCE Serves as a Potential Prognostic Biomarker and is Associated With Immune Infiltrates in Breast Cancer

Huo

Xie

2020

Preprint

View full text Add to dashboard Cite

Background: Von Willebrand Factor C and EGF Domains (VWCE) is an important gene that regulates cell adhesion, migration, and interaction. However, the correlation between VWCE expression and immune inﬁltrating in breast cancer remain unclear. In the study, we investigated the correlation between VWCE expression and immune infiltration levels in breast cancer.Methods: VWCE expression was analyzed by the tumor immune estimation resource (TIMER) and DriverDB database. Furthermore, genes co-expressed with VWCE and gene ontology (GO) enrichment analysis were investigated by the STRING and Enrichr web servers. Also, we performed the single nucleotide variation (SNV), copy number variation (CNV), and pathway activity analysis by GSCALite. Subsequently, the relationship between VWCE expression and tumor immunity was analyzed by TIMER and TISIDB database, and further verified the results using immunohistochemistry. Results: The results showed that the expression of VWCE mRNA in breast cancer tissue was significantly lower than that in normal tissue. We found that the expression level of VWCE was associated with subtypes, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) status of patients with breast cancer, while no significant expression difference of VWCE mRNA was found in age and nodal status. Further analyses indicated that VWCE was correlated with the activation or inhibition of multiple oncogenic pathways. Additionally, VWCE expression showed negatively correlated with the expression of STAT1 (Th1 marker, r = -0.12, p = 6e-05), but positively correlated with the expression of MS4A4A (r = 0.28, p = 0). These results suggested that the expression of VWCE was significantly correlates the immune infiltration levels of Th1 and M2 macrophage in breast cancer. Conclusions: The high expression of VWCE indicates a better prognosis and associated with immune infiltration in breast cancer. These findings demonstrate that VWCE is a potential prognostic biomarker correlated with tumor immune cell infiltration, and maybe a promising therapeutic target in breast cancer.

show abstract

Surface marker profiles on lung lymphocytes may predict the mechanism of immune-mediated pneumonitis triggered by tumor-infiltrating lymphocytes in lung cancer patients treated with pembrolizumab

Cited by 15 publications

References 8 publications

Immune-related adverse events caused by treatment with pembrolizumab in a patient with lung cancer who infected influenza virus

Immune-related adverse events caused by treatment with pembrolizumab in a patient with lung cancer who infected influenza virus

Real-world experience with pembrolizumab in patients with advanced soft tissue sarcoma

VWCE Serves as a Potential Prognostic Biomarker and is Associated With Immune Infiltrates in Breast Cancer

Contact Info

Product

Resources

About

Surface marker profiles on lung lymphocytes may predict the mechanism of immune-mediated pneumonitis triggered by tumor-infiltrating lymphocytes in lung cancer patients treated with pembrolizumab

Cited by 15 publications

References 8 publications

Immune-related adverse events caused by treatment with pembrolizumab in a patient with lung cancer who infected influenza virus

Immune-related adverse events caused by treatment with pembrolizumab in a patient with lung cancer who infected influenza virus

Real-world experience with pembrolizumab in patients with advanced soft tissue sarcoma

VWCE&nbsp;Serves as a Potential Prognostic Biomarker and is Associated With Immune Infiltrates in Breast Cancer

Contact Info

Product

Resources

About

VWCE Serves as a Potential Prognostic Biomarker and is Associated With Immune Infiltrates in Breast Cancer